M Hoffmann

Ruhr-Universität Bochum, Bochum, North Rhine-Westphalia, Germany

Are you M Hoffmann?

Claim your profile

Publications (8)7.24 Total impact

  • [Show abstract] [Hide abstract]
    ABSTRACT: Dystrophic epidermolysis bullosa is a group of inherited skin blistering disorders caused by mutations in the COL7A1 gene coding for type VII collagen. More than 500 different COL7A1 mutations have been detected in dystrophic epidermolysis bullosa to date. Clarification of genotype-phenotype correlations is of particular importance for the development of novel therapeutic approaches. Here we report a female patient with mild dystrophic epidermolysis bullosa harbouring two compound heterozygous COL7A1 mutations, namely the intronic splice site mutation c.3832-2A > G and the glycine substitution p.G1347W. Our data extend the current knowledge on genotype-phenotype correlations in dystrophic epidermolysis bullosa.
    European journal of dermatology: EJD 02/2011; 21(2):170-2. · 1.76 Impact Factor
  • M Stücker, M Hoffmann, P Altmeyer
    [Show abstract] [Hide abstract]
    ABSTRACT: Retinoids like tazarotene are approved for the treatment of chronic plaque psoriasis. In the beginning of topical retinoid therapy, 15-20% of the patients suffer from mild to moderate adverse reactions with burning and erythema. The aim of the study was to find predicative parameters of the individual irritative potential and to suggest options to reduce these initial irritations. Twenty in-patients with different skin types (1 + 2: 11, 3 + 4: 9), with chronic plaque psoriasis were included in this open study. In each patient, 7 randomized plaques on the forearm were treated for 14 days on different ways: test area 1: morning (m) and evening (e) placebo, test area 2: placebo (m) and tazarotene 0.05% (e), test area 3: placebo (m) and tazarotene 0.1% (e), test area 4: calcipotriol (m) and calcípotriol (e), test area 5: mometasone furoate (m) and tazarotene 0.05% (e), test area 6: mometasone furoate (m) and tazarotene 0,1% (e), test area 7: placebo (m) and tazarotene in increasing concentrations (e), test area 8: healthy skin for control. Before and after therapy, skin barrier function, blood flow and plaque thickness in 20-MHz sonography were assessed in different test areas intraindividually by non- invasive biophysical measurements. After 14 days of therapy, tazarotene 0.05% and 0.1% produced a stronger increase of laser Doppler flow in patients with skin type 1 and 2 than in patients with skin type 3 and 4. When using the combination therapy of tazarotene and mometasone, the laser Doppler flow was significantly lower than in tazarotene as monotherapy. 20-MHz-ultrasound showed a significant decrease in the thickness of the echo-poor band in all topical therapy regimens compared to placebo. Patients of skin type 1 and 2 reached a higher density of the dermis than patients of skin type 3 and 4, meaning a stronger decrease of inflammatory infiltration and acanthosis. Adapting retinoid therapy to the patient's skin type can reduce the initial irritative side-effects. During the first days, patients with skin type 1 or 2 should add a medium potency corticosteroid. Stronger skin irritation caused by tazarotene therapy increases therapy effects.
    Skin Research and Technology 06/2002; 8(2):133-40. · 1.41 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Malignant melanomas show a higher heterogeneity in their architecture and a higher vessel density because of neovascularization compared to benign melanocytic skin tumours. In this study the validity of the newly developed Laser Doppler Perfusion Imager (LDPI) with a lateral resolution of 100 microns in the differential diagnosis of pigmented skin tumours was investigated. The perfusion of 116 pigmented skin tumours was s measured with LDPI; 44 malignant melanomas, five melanoma metastases, 59 dysplastic nevi and eight basal cell carcinomas were studied before excision for precise histological diagnosis. There is a significantly higher perfusion of the malignant melanomas (3.15 +/- 1.87 AU) compared to dysplastic nevi (1.14 +/- 0.97 AU) (p < 0.01). By calculating a ratio of the mean perfusion in the tumour and the mean perfusion in adjacent healthy skin, the potential source of error because of regional differences in perfusion is eliminated. The ratio of malignant melanomas (10.78 +/- 9.18) is significantly higher than these of melanoma metastases (4.20 +/- 1.66), basal cell carcinomas (3.24 +/- 1.32) and dysplastic nevi (2.85 +/- 1.32). The high resolution LDPI has the potential to be a non-invasive screening method for preoperative differential diagnosis of pigmented skin tumours. Besides the epiluminescence microscopy and sonographic determination of the tumour thickness, we have now the possibility to get preoperative information about tumour vascularization.
    Der Hautarzt 05/2002; 53(4):244-9. · 0.50 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Hintergrund und Fragestellung. Maligne Melanome zeichnen sich gegenüber gutartigen melanozytären Tumoren durch eine verstärkte Heterogenität ihrer Architektur und einer höheren Gefäßdichte infolge Neovaskularisation aus. Die Aussagekraft eines neu entwickelten Laser-Doppler-Perfusion-Imager (LDPI) mit einer hohen lateralen Auflösung von 100 μm wurde für die Differenzialdiagnostik kutaner Tumoren aufgrund unterschiedlicher Perfusionsmuster geprüft. Patienten/Methodik. Es werden 116 Hauttumoren mittels LDPI vermessen: 44 maligne Melanome, 5 Melanomfiliae, 59 atypische Nävuszellnävi und 8 Basalzellkarzinome. Nach der Exzision erfolgt die histologische Aufarbeitung aller Tumoren. Ergebnisse. Maligne Melanome (3,15±1,87 AU) zeigen eine im Vergleich zu dysplastischen Nävuszellnävi (1,14±0,97 AU) signifikant höhere Perfusion (p<0,01). Durch die Berechnung der Ratio aus der Perfusion im Tumor und der Perfusion in gesunder Haut wird die potenzielle Fehlerquelle infolge regionaler Perfusionsunterschiede eliminiert. Maligne Melanome zeigen eine signifikant höhere Ratio (10,78±9,18) als Melanomfiliae (4,20±1,66), Basalzellkarzinome (3,24±1,32) und atypische Nävi (2,85±1,32). Schlussfolgerungen. Das hochauflösende LDPI hat das Potenzial einer nichtinvasiven Screening-Methode in der präoperativen Abklärung der Dignität von Hauttumoren. Neben der Auflichtmikroskopie und der sonographischen Dickenbestimmung können nun Informationen zur Durchblutung der Hauttumore zur präoperativen Diagnostik genutzt werden. Background and Objective. Malignant melanomas show a higher heterogeneity in their architecture and a higher vessel density because of neovascularization compared to benign melanocytic skin tumours. In this study the validity of the newly developed Laser Doppler Perfusion Imager (LDPI) with a lateral resolution of 100 μm in the differential diagnosis of pigmented skin tumours was investigated. Patients/Methods. The perfusion of 116 pigmented skin tumours was s measured with LDPI; 44 malignant melanomas, five melanoma metastases, 59 dysplastic nevi and eight basal cell carcinomas were studied before excision for precise histological diagnosis. Results. There is a significantly higher perfusion of the malignant melanomas (3,15±1,87 AU) compared to dysplastic nevi (1,14±0,97 AU) (p<0,01). By calculating a ratio of the mean perfusion in the tumour and the mean perfusion in adjacent healthy skin, the potential source of error because of regional differences in perfusion is eliminated. The ratio of malignant melanomas (10,78±9,18) is significantly higher than these of melanoma metastases (4,20±1,66), basal cell carcinomas (3,24±1,32) and dysplastic nevi (2,85±1,32). Conclusions. The high resolution LDPI has the potential to be a non-invasive screening method for preoperative differential diagnosis of pigmented skin tumours. Besides the epiluminescence microscopy and sonographic determination of the tumour thickness, we have now the possibility to get preoperative information about tumour vascularization.
    Der Hautarzt 03/2002; 53(4):244-249. · 0.50 Impact Factor
  • Aktuelle Dermatologie 01/2001; 27(6):173-177.
  • Biomedizinische Technik - BIOMED TECH. 01/2001; 46:88-89.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: There are already many effective topical therapies available for use in the treatment of chronic plaque psoriasis. Unfortunately, these treatments are often associated with a rather significant risk of undesirable effects. In this randomized, prospective clinical trial, the effects of the vitamin D(3) analog calcipotriol were evaluated against those of a recently developed vitamin B(12) cream containing avocado oil in an intraindividual right/left-side comparison. The trial population consisted of 13 patients, 10 men and 3 women, with chronic plaque psoriasis. The observation period was 12 weeks; the effects of therapy were assessed on the basis of a PASI score adapted to the right/left-side comparison technique, the subjective evaluations of the investigator and patients and the results of 20-MHz sonography. There was a more rapid development of beneficial effects with the use of calcipotriol in the initial 8 weeks, although differences in effects were significant only at the time point of therapy week 8 (p < 0.05). After 12 weeks, neither the PASI score nor 20-MHz sonography showed significant differences between the two treatments. While the efficacy of the calcipotriol preparation reached a maximum in the first 4 weeks and then began to subside, the effects of the vitamin B(12) cream containing avocado oil remained at a constant level over the whole observation period. This would indicate that the vitamin B(12) preparation containing avocado oil may be suitable for use in long-term therapy, a hypothesis further supported by the fact that the investigator and the patients assessed the tolerability of the vitamin B(12) cream containing avocado oil as significantly better in comparison with that of calcipotriol. The results of this clinical trial provide evidence that the recently developed vitamin B(12) cream containing avocado oil has considerable potential as a well-tolerated, long-term topical therapy of psoriasis.
    Dermatology 01/2001; 203(2):141-7. · 2.02 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Various therapies for morphea have been used with limited success, including ones with potentially hazardous side effects. When morphea occurs in childhood it may lead to progressive and long-lasting induration of the skin and subcutaneous tissue, growth retardation, and muscle atrophy. We report an open prospective study in which the efficacy of a combined treatment with calcipotriol ointment and low-dose ultraviolet A1 (UVA1) phototherapy in childhood morphea was investigated. Nineteen children (mean age 8.5 years, range 3-13 years) with morphea were exposed to UVA1 (340-400 nm) phototherapy at a dose of 20 J/cm(2) four times a week for 10 weeks. Forty phototherapy sessions resulted in a cumulative dose of 800 J/cm(2) UVA1. In addition, calcipotriol ointment (0.005%) was applied twice a day. After 10 weeks, palpation and inspection showed a remarkable softening and repigmentation of formerly affected skin resulting in a highly significant (p < 0.001) decrease of the mean clinical score from 7.3 +/- 0.9 at the beginning to 2.4 +/- 0.9 (relative reduction 67.1%) at the end of combined therapy. Our results indicate that a combined therapy with calcipotriol ointment and low-dose UVA1 phototherapy is highly effective in childhood morphea. Further controlled studies are necessary to investigate whether this combined therapy is superior to UVA1 phototherapy alone.
    Pediatric Dermatology 18(3):241-5. · 1.04 Impact Factor